Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...

The obesity market has garnered much interest lately, propelled by the success of GLP-1 therapies Wegovy and Zepbound, marketed by pharma giants Novo Nordisk NVO and Eli Lilly LLY, respectively. This ...

The findings add to other research showing a lower risk of obesity-related cancers in patients taking GLP-1 drugs, a class of ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.